The Global Valvular Disease Interventional Device Market was valued at USD 7,851 Million in 2023 and is projected to reach USD 22,301.95 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.30% during the forecast period (2023–2032). This growth is being driven by rising incidences of valvular heart diseases, aging populations worldwide, and the accelerating adoption of minimally invasive procedures like TAVR (Transcatheter Aortic Valve Replacement) and TMVR (Transcatheter Mitral Valve Replacement) systems, which offer lower risks and faster recovery compared to traditional open-heart surgery.
As the cardiovascular healthcare sector shifts toward less invasive treatments and enhanced patient outcomes, the focus turns to the pioneering device manufacturers who are pushing the boundaries of precision engineering, clinical efficacy, and accessibility. In this blog, we profile the Top 10 Companies in the Valvular Disease Interventional Device Industry—a blend of established medtech leaders and innovative specialists redefining interventional cardiology for global patients.
🔟 1. Edwards Lifesciences
Headquarters: Irvine, California, USA
Key Offering: SAPIEN TAVR Systems, CardiAQ TMVR
Edwards Lifesciences stands as a global frontrunner in structural heart devices, with its SAPIEN platform dominating the TAVR space through thousands of successful implants annually. The company excels in developing next-generation valves that minimize complications and improve long-term durability for patients with aortic stenosis, serving hospitals and cardiac centers across North America, Europe, and Asia.
Innovation Initiatives:
-
Advancing self-expanding valve technologies for complex anatomies
-
Clinical trials expanding TAVR indications to younger, lower-risk patients
-
Commitment to reducing procedural times and enhancing imaging integration
Download FREE Sample Report: Valvular Disease Interventional Device Market – View in Detailed Research Report
9️⃣ 2. Medtronic
Headquarters: Dublin, Ireland (Global HQ); Minneapolis, Minnesota, USA
Key Offering: CoreValve Evolut TAVR Platform, Intrepid TMVR
Medtronic’s structural heart division leads with recapturable and repositionable valve systems that have transformed TAVR outcomes, particularly for high-risk patients. Operating in over 150 countries, the company supports extensive training programs for interventional cardiologists and invests heavily in R&D to address mitral and tricuspid valve challenges.
Innovation Initiatives:
-
Development of fully repositionable TMVR devices for mitral regurgitation
-
Partnerships with regulatory bodies to accelerate approvals in emerging markets
8️⃣ 3. Abbott Laboratories
Headquarters: Abbott Park, Illinois, USA
Key Offering: MitraClip TMVr System, Navitor TAVR
Abbott has revolutionized mitral valve interventions with its MitraClip, a clip-based repair device that avoids full replacement in many cases. The company’s portfolio extends to TAVR with the supra-annular Navitor system, emphasizing ease of use and reduced paravalvular leak rates, making it a preferred choice in ambulatory surgical settings worldwide.
Innovation Initiatives:
-
Expansion of TMVr applications to include secondary mitral regurgitation
-
Integration of AI-driven imaging for precise device deployment
7️⃣ 4. Boston Scientific
Headquarters: Marlborough, Massachusetts, USA
Key Offering: Lotus Edge TAVR, Acurate neo2 TAVR
Boston Scientific continues to innovate in the TAVR arena with its adaptive seal technology that enhances valve positioning and reduces embolization risks. The company focuses on European and Asian markets, where regulatory pathways favor their low-profile delivery systems, and is actively pursuing TMVR advancements through strategic acquisitions.
Innovation Initiatives:
-
Targets for broader TAVR use in bicuspid valve patients
-
Collaborations with key opinion leaders to refine TPVR (Transcatheter Pulmonary Valve Replacement) options
Download FREE Sample Report: Valvular Disease Interventional Device Market – View in Detailed Research Report
6️⃣ 5. Venus Medtech
Headquarters: Hangzhou, China
Key Offering: VenusP-Valve for TR, VitaFlow TAVR
Venus Medtech is a rising star in Asia, offering cost-effective TAVR solutions tailored to diverse patient anatomies common in the region. Their devices have gained traction in China and Southeast Asia, with ongoing expansions into Europe, supported by robust clinical data demonstrating comparable efficacy to Western counterparts.
Innovation Initiatives:
-
Focus on tricuspid valve interventions with self-centering designs
-
Aim to localize manufacturing for faster market access in APAC
5️⃣ 6. Meril Life Sciences
Headquarters: Vapi, Gujarat, India
Key Offering: Myval TAVR Series, MyMitra TMVR
Meril Life Sciences is driving affordability in the Indian subcontinent and beyond with its indigenous TAVR valves, which feature modular sizing for better fit across ethnic variations. The company has conducted pivotal trials in India and is scaling exports to the Middle East and Africa, emphasizing training for local interventionalists.
Innovation Initiatives:
-
Current output: Over 1,000 implants annually in emerging markets
-
Target: Double clinical enrollment for TMVR by 2026
4️⃣ 7. Braile Biomedica
Headquarters: São José do Rio Preto, Brazil
Key Offering: Braile TAVR, Mitral Repair Devices
Braile Biomedica plays a crucial role in Latin America, supplying TAVR devices optimized for regional healthcare infrastructures. As the leading provider in South America, it supports national registries and focuses on post-market surveillance to refine devices for rheumatic heart disease prevalent in the area.
Innovation Initiatives:
-
R&D in bioresorbable components for valve-in-valve procedures
-
Public-private partnerships to expand access in underserved regions
3️⃣ 8. LivaNova PLC
Headquarters: London, United Kingdom
Key Offering: Perceval Sutureless Valve, Perceval TMVR Adaptations
LivaNova specializes in sutureless and rapid-deployment valves that shorten surgical times, bridging traditional and interventional approaches. With a strong European footprint, the company is transitioning more products to fully transcatheter formats, serving cardiac catheterization labs efficiently.
Innovation Initiatives:
-
Indigenous development of hybrid valve systems
-
Collaborations for large-scale registries in EU markets
2️⃣ 9. JenaValve Technology
Headquarters: Munich, Germany
Key Offering: JenaValve Trilogy TAVR System
JenaValve excels in location-based anchoring technology for TAVR, ideal for challenging aortic roots. Acquired by Edwards but operating independently, it targets high-risk patients in Europe and the US, with expansions into aortic regurgitation treatments that few competitors address.
Innovation Initiatives:
-
Aims to achieve CE Mark expansions for off-label uses
-
Major clinical trials underway for broader indications
Download FREE Sample Report: Valvular Disease Interventional Device Market – View in Detailed Research Report
1️⃣ 10. Colibri Heart Valve LLC
Headquarters: Irvine, California, USA
Key Offering: Colibri TMVR System, Transseptal Delivery Platforms
Colibri Heart Valve focuses on next-generation TMVR with its tri-leaflet, supra-annular design that preserves native anatomy. Supporting over 500 global sites, it leads in distribution logistics and carbon-neutral manufacturing practices for sustainable medtech.
Innovation Initiatives:
-
End-to-end solutions for mitral interventions in ambulatory centers
-
Strategic alliances with imaging firms for real-time guidance
Get Full Report Here: Valvular Disease Interventional Device Market – View in Detailed Research Report
🌍 Outlook: The Future of Valvular Disease Interventional Devices Is Minimally Invasive and Accessible
The valvular disease interventional device market is experiencing rapid evolution. While TAVR remains dominant, investments are surging in TMVR and TPVR to address unmet needs in mitral and pulmonary valves, alongside expanded access in developing regions.
📈 Key Trends Shaping the Market:
-
Accelerated regulatory approvals for lower-risk patient expansions in the US, EU, and Asia
-
Mandates for cost-effective devices in national health programs by 2030
-
Integration of robotics and AI for procedure precision and training
-
Strategic mergers among medtech firms to consolidate R&D efforts
Market Trends Affecting Valvular Disease Interventional Devices
-
Advancements in valve durability and biocompatibility — newer materials like tissue-engineered leaflets extend device lifespan, reducing reinterventions. Edwards Lifesciences’ anti-calcification coatings set a benchmark here.
-
Shift toward ambulatory and hybrid procedures — with shorter recovery times, TAVR and TMVR are moving to outpatient settings, aided by next-gen delivery systems that minimize vascular complications. Abbott’s guidewire innovations exemplify this.
-
Personalized medicine through imaging and simulation — pre-procedural CT and 3D modeling (from Medtronic partnerships) allow custom valve sizing, improving outcomes in complex cases like bicuspid aortopathy.
-
Emerging market penetration and local manufacturing — companies like Venus Medtech and Meril are localizing production to cut costs and navigate tariffs, fueling growth in India and China where valvular disease burdens are high.
-
Focus on multi-valve interventions — simultaneous TAVR-TMVR combos are in trials, with Boston Scientific leading to address polyvalvular disease in elderly patients more holistically.
Get Full Report Here: Valvular Disease Interventional Device Market – View in Detailed Research Report
The companies listed above are not only transforming cardiac care—they’re pioneering the minimally invasive era of valvular interventions, saving lives with precision and speed.